The goals of this proposal are to develop non-replicating, rapidly acting mucosal vaccines capable of eliciting effective cross-protection against both Burkholderia mallei (Bm) and 6. pseudomallei (Bpm) pneumonic infection. This project will utilize cationic liposome-nucleic acid complex (CLDC) adjuvants for mucosal immunization (intranasal and oral administration) with Burkholderia antigens. The antigens to be evaluated include 7 Bm antigens, all of which have been shown to elicit at least partial protection in published or preliminary studies. We will test the hypothesis that effective cross-protection against inhaled B. mallei and B pseudomallei infection can be achieved bv mucosal administration of liposome-nucleic acid adiuvanted vaccines containing one to two immunogenic Burkholderia antigens. To test this hypothesis, we will undertake the following 4 specific aims.
In Aim 1. the ability of Bm antigens to elicit cross-protection against both Bm and Bpm infection will be assessed. Mice will be immunized with CLDC-based vaccines containing recombinant Bm antigens and subjected to inhalational challenge with Bm and 6pm.
In Aim 2. the CLDC adjuvant platform will be optimized for efficient mucosal immunization and the two most effective antigens from Aim 1 will be assessed for their ability to elicit protection in high-dose Bm and Bpm challenge studies following oral and intranasal immunization. The immunological mechanisms responsible for vaccine-induced protection, including humoral and cellular effector mechanisms, will be assessed in Aim 3. Finally, in Aim 4 we will determine whether combining mucosal vaccination with conventional antimicrobial therapy can generate improved protection from acute infection and prevent the establishment of chronic Burkholderia infection. This research project fits within the RMRCE Integrated Research Focus on Immunomodulation, Adjuvants and Vaccines, and will interact directly with RP 1.4 (Francisella immunoproteome) and RP 1.2 (Development of innate adjuvants) and will utilize the resources of Animal Models and Human Lung Cell Cores. RCRME objectives. Studies of Burkholderia immunity and development of new vaccines and adjuvants are priorities for the RMRCE program. The studies proposed here will identify new Burkholderia vaccine antigens and advance development of a broadly effective mucosal vaccine adjuvant suitable for protection of civilian and military populations from aerosolized Burkholderia infection. The vaccine adjuvant platform being developed here is also applicable to immunization against a number of other bacterial and viral pathogens.

Public Health Relevance

In this proposal we will develop mucosally administered vaccines designed to rapidly generate protection from acute pneumonia caused by inhalation of Burkholderia mallei and 8. pseudomallei infection. We will also determine whether combining mucosal vaccination with conventional antibiotic therapy can provide additional protection from infection with these important bacterial pathogens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-09
Application #
8465796
Study Section
Special Emphasis Panel (ZAI1-DDS-M)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
9
Fiscal Year
2013
Total Cost
$202,190
Indirect Cost
$51,622
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450
Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463
Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:
Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002
Rhodes, Katherine A; Schweizer, Herbert P (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82-90
Lehman, Stephanie S; Mladinich, Katherine M; Boonyakanog, Angkana et al. (2016) Versatile nourseothricin and streptomycin/spectinomycin resistance gene cassettes and their use in chromosome integration vectors. J Microbiol Methods 129:8-13
Rico, Amber B; Phillips, Aaron T; Schountz, Tony et al. (2016) Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses. Virology 499:30-39
Calvert, Amanda E; Dixon, Kandice L; Piper, Joseph et al. (2016) A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease. Antiviral Res 131:92-9
Westover, Jonna B; Sefing, Eric J; Bailey, Kevin W et al. (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126:62-8

Showing the most recent 10 out of 253 publications